AIN457

Phase 3Small molecule

Novartis

AIN457 is one of 250 small molecule programs targeting Polymyalgia Rheumatica. It is currently in Phase 3.

Indications

Total Trials

Active Trials

249

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polymyalgia RheumaticaActive, not recruiting

ArthritisActive, not recruiting

Relapsing-Remitting Multiple SclerosisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Multiple SclerosisActive, not recruiting

AsthmaActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

UveitisActive, not recruiting

Polymyalgia RheumaticaPhase 2

Active, not recruiting

ArthritisPhase 3

Active, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

PsoriasisPhase 1/Phase 2

Active, not recruiting

Psoriatic ArthritisPhase 3

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Ankylosing SpondylitisPhase 3

Active, not recruiting

UveitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

AIN457

Novartis

Phase 3

1 2

Veramyst

GSK

Preclinical

46 3

Xolair

Roche

Preclinical

25 4

Asmanex

Novartis

Preclinical

5 5

Celexa

AbbVie

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

Paracetamol

GSK

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

2 9

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis10 trials

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

Completed· Novartis logo

Novartis·Phase 2·NCT00770965·80 enrolled

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Completed· Novartis logo

Novartis·Phase 2·NCT00941031·404 enrolled

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Completed· Novartis logo

Novartis·Phase 2·NCT01132612·275 enrolled

Show 7 more trials

A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

Completed· Novartis logo

Novartis·Phase 1/2·NCT00669916·36 enrolled

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Completed· Novartis logo

Novartis·Phase 3·NCT02074982·676 enrolled

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Completed· Novartis logo

Novartis·Phase 3·NCT01640951·675 enrolled

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Completed· Novartis logo

Novartis·Phase 3·NCT01406938·967 enrolled

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Completed· Novartis logo

Novartis·Phase 2·NCT01071252·125 enrolled

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Completed· Novartis logo

Novartis·Phase 1·NCT02607774·25 enrolled

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

Completed· Novartis logo

Novartis·Phase 2·NCT00805480·130 enrolled

Uveitis6 trials

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Terminated· Novartis logo

Novartis·Phase 3·NCT01095250·30 enrolled

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Terminated· Novartis logo

Novartis·Phase 3·NCT01032915·125 enrolled

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Terminated· Novartis logo

Novartis·Phase 3·NCT01090310·86 enrolled

Show 3 more trials

Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01327664

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01103024

Safety and Efficacy of AIN457 in Noninfectious Uveitis

Completed· Novartis logo

Novartis·Phase 2·NCT00685399·76 enrolled

Psoriatic Arthritis3 trials

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

Completed· Novartis logo

Novartis·Phase 3·NCT02662985·166 enrolled

Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Completed· Novartis logo

Novartis·Phase 2·NCT00809614·42 enrolled

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT04209205·381 enrolled

Ankylosing Spondylitis2 trials

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

Completed· Novartis logo

Novartis·Phase 2·NCT00809159·60 enrolled

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Completed· Novartis logo

Novartis·Phase 3·NCT03259074·859 enrolled

Rheumatoid Arthritis2 trials

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

Completed· Novartis logo

Novartis·Phase 1/2·NCT00669942·104 enrolled

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Phase III Study in Refractory Behcet's Disease

Completed· Novartis logo

Novartis·Phase 3·NCT00995709·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for AIN457. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AIN457 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AIN457. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

AIN457

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis10 trials

Uveitis6 trials

Psoriatic Arthritis3 trials

Ankylosing Spondylitis2 trials

Rheumatoid Arthritis2 trials

Polymyalgia Rheumatica1 trial

Multiple Sclerosis1 trial

Relapsing-Remitting Multiple Sclerosis1 trial

Crohn's Disease1 trial

Trial1 trial

Arthritis1 trial

AIN1 trial

Efficacy and Safety1 trial

Asthma1 trial

Steroid1 trial

Moderate to Severe Crohn's Disease1 trial

Behcet's Disease1 trial

References

Drug Info

Quick Facts

Related News